Description of Medical ServiceIt is proposed that immunohistochemistry (IHC) test for evaluation of Programmed Cell Death- Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab, be undertaken in patients diagnosed with unresectable or metastatic bladder cancer. The tissue removed as part of a standard biopsy will be used for immunohistochemical testing with PD-L1. The testing would be done by a pathologist alongside other immunohistochemical tests which are done routinely, and it would be proposed that the test is a pathologist determinable test.
Description of Medical ConditionStage IV advanced/metastatic bladder cancer. Patients with stage IV bladder cancer have cancer that has extended through the bladder wall and invaded the pelvic and/or abdominal wall and/or has lymph node involvement and/or spread to distant sites. Stage IV bladder cancer is also referred to as “unresectable or metastatic” bladder cancer.
Reason for ApplicationNew MBS item
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Application form (PDF 275 KB)
Application form (Word 541 KB)
PICO ConfirmationPICO Confirmation (PDF 349 KB)
PICO Confirmation (Word 693 KB)